Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanoManganese in Moderate to Severe COVID-19
NCT05451654Phase 2Terminated
- Sponsor
- Medesis Pharma
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NanoManganese in coronavirus disease 2019 (COVID-19), sponsored by Medesis Pharma. Started Feb 2022; status: terminated.
02
Drugs
NanoManganese
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05451654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451654.